Gilead Sciences, Inc. - Common Stock (GILD)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Aug 24, 2026Investment Snapshot
- Trading 173% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -29.3%
- Dividend yield of 2.2%
Gilead Sciences, Inc. - Common Stock (GILD) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $181.2 billion . Key value metrics: P/E ratio 21.7, P/B ratio 15.32, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Gilead Sciences, Inc. - Common Stock — Fundamental Analysis Summary
Gilead Sciences, Inc. - Common Stock (GILD) is currently trading 173% above its Graham Number of $53.53, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 21.7x.
On financial health, GILD shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -29.3% (sector average: -20.1%), and high leverage with a debt-to-equity ratio of 2.42.
StockPik's composite Value Score for GILD is 25/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
GILD reports a high gross margin of 79.4% (sector average: 37.4%) and a negative operating margin of -6.8%.
GILD shows revenue growing at 2% year-over-year, with earnings growing at 1,673%.
GILD pays a modest dividend yield of 2.2%.